Replies to Post #22188 onItonis Inc (ITNS)

Replies to #22188 on Itonis Inc (ITNS)

06/06/14 1:08 PM

#22400 RE: sunspotter #22188

In my view, the only possible reason they could have for obtaining an NDC was to deceive naive investors by enabling their PR.

Come on now sunspotter, you know this is total garbage.

Any homeopathic product that is sold in the U.S must have an NDC number. It isn't optional:

http://www.fda.gov/downloads/AboutFDA/WorkingatFDA/FellowshipInternshipGraduateFacultyPrograms/PharmacyStudentExperientialProgramCDER/UCM255181.pdf

As is made clear in the article, the term "drug" includes:

(A) articles recognized in the official United States Pharmacopeia, official Homeopathic Pharmacopeia of the United States, or official National Formulary, or any supplement to any of them

The PR just confirms that this necessary step in preparing the product for sale is complete. The company is making a factual statement that by obtaining an NDC, it is in compliance with FDA requirements and that Emesyl can begin the manufacturing phase. Where is the attempt to deceive ? I don't see any words implying that the FDA has "approved" this product ?

Are you suggesting that investors should not be made aware of hurdles that are being crossed in the process of preparing Emesyl for public sale? Should the company avoid issuing PR's for fear that information could be misconstrued ? How would we know what was going on ?

Other moderators: The claim that "the NDC PR and related ballyhoo was put out there simply to allow ITNS' paid stock pimps to conflate and confuse allowance of an NDC code with NDA approval" has no real basis, as I have explained in my post. I request that post #22188 should be 'unstickied'.